3 US Healthcare Stocks In Focus As California Wealth Tax Spurs Funding Debate

California’s proposed Proposition 40 wealth tax has pushed healthcare funding to the front page, and that policy shock is now rippling through hospital operators and managed-care stocks. Investors watching potential billionaires’ capital flight are also weighing where an extra US$100b for health programs might land. This article unpacks that story and highlights three US healthcare providers with exposure to this debate so you can assess the potential implications for your portfolio.

The three stocks covered below are just a small sample, and the full investment idea screen surfaced 29 more US healthcare providers and managed-care companies with equally compelling stories tied to this policy backdrop. If you want to move quickly from headlines to hard data, head straight into the US Healthcare Providers and Managed Care Stocks screener to identify, filter, and analyze your highest-conviction candidates.

Alignment Healthcare (ALHC)

Alignment Healthcare sits near the center of this screener’s theme because its Medicare Advantage plans directly plug into the government-backed funding that Proposition 40 is trying to reinforce for California’s seniors.

Alignment Healthcare runs a consumer-focused Medicare Advantage platform for US seniors, generating about US$4.6b from providing healthcare services in the United States and carrying a roughly US$1.7b market cap.

"Alignment Healthcare's business model is highly exposed to the risk of declining government reimbursement, as rising healthcare costs and fiscal pressures may prompt CMS to tighten Medicare Advantage payments, directly threatening future revenue growth and compressing margins over the next several years."

What happens if a single pressure point on this government-backed revenue stream shifts just a little further than investors currently expect?

If that pressure starts to build, full narrative for Alignment Healthcare shows how Alignment Healthcare’s risk could be masking underappreciated upside.

InnovAge Holding (INNV)

InnovAge Holding is directly connected to the seniors care theme of this screen, operating PACE centers that bundle medical and support services for older adults. Almost all of its roughly US$989 million in revenue comes from PACE programs in the US, and the stock has a market cap of about US$1.3 billion.

For investors tracking how Proposition 40 could support Medicare- and Medicaid-backed care models in California, InnovAge Holding offers a real-time test case of what tighter execution can do within a reimbursement-heavy seniors platform.

"Operational improvements and alignment with value-based care are driving margin improvements and better medical expense control."

The key variable is how one pressure point in its funding and cost structure ultimately affects future earnings power.

That funding hinge is exactly what the full narrative for InnovAge Holding unpacks, revealing how InnovAge Holding’s model could accelerate if execution and policy support continue to move in the same direction.

Centene (CNC)

Centene plugs directly into the screener theme through its large Medicaid and government-backed health plans. This gives you exposure to state funding decisions like California’s while also tying in Medicare and commercial coverage for under-insured families and employers.

Centene generates most of its US$180.3b in US revenue from Medicaid at about US$92.6b, with Medicare at roughly US$40.4b, Commercial close to US$40.7b, and Other services around US$5.0b, and the stock carries a market value of roughly US$35.2b.

"Centene's effort to restore Medicaid margins, supported by a 2026 composite rate yield outlook of roughly 5% and a targeted full year Medicaid HBR of about 93.5%, continues to point to earnings power that some investors may not yet fully reflect in valuation."

What happens if one less visible shift in how governments pay for care changes the balance between restored margins and future growth potential?

To see how that inflection could play out in full, read the full narrative for Centene and assess where Centene’s earnings power might be decoupling from headline worries.

Seeking Alternatives Before The Crowd

Fresh breakout stories move quickly and momentum money rarely waits. Spot ideas still flying under the radar for now and pressure test them while it matters, act now.

• Chase quality at a discount by scanning a curated batch of resilient businesses in the 27 high quality undervalued stocks before valuations get caught up by the crowd.
• Ride real earnings momentum by tracking cash generative tech players using the 39 profitable AI stocks that aren't just burning cash while enthusiasm for AI is high and weaker stories keep dropping away.
• Target steady cash returns by reviewing a hand picked pool of high yield payers in the 5 dividend fortresses before income hunters compress those payouts further.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com